Akebia Therapeutics
AKBA
133 hedge funds and large institutions have $219M invested in Akebia Therapeutics in 2021 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 43 increasing their positions, 35 reducing their positions, and 20 closing their positions.
672% more call options, than puts
Call options by funds: $5.2M | Put options by funds: $674K
40% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 20
23% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 35
6% more funds holding
Funds holding: 126 → 133 (+7)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.09% less ownership
Funds ownership: 56.43% → 55.34% (-1.1%)
23% less capital invested
Capital invested by funds: $284M → $219M (-$64.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$5.25M |
| 2 |
Goldman Sachs
New York
|
+$4.45M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.25M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.36M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$1.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$11.2M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$6.8M |
| 3 |
PIMJS
PKO Investment Management Joint-Stock
Warsaw,
Poland
|
-$1.79M |
| 4 |
Prudential Financial
Newark,
New Jersey
|
-$1.24M |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$897K |
AKBA Hedge Fund Activity: Q4 2021 in Review
133 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q4 2021, worth a combined $219M — down 23% from $284M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new AKBA positions and 20 closed out — a net gain of 8 holders — while 43 added to existing stakes and 35 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $5.25M. The largest seller was State Street, cutting an estimated $11.2M.
- 133 institutional investors held Akebia Therapeutics (AKBA) as of Q4 2021, up from 126 in Q3 2021.
- Funds reported $219M of Akebia Therapeutics stock for Q4 2021, down 23% quarter-over-quarter.
- 28 funds opened new Akebia Therapeutics positions in Q4 2021 and 20 closed out, a net change of +8 holders.
- The largest Akebia Therapeutics buyer in Q4 2021 was Millennium Management, an estimated $5.25M added.
- The largest Akebia Therapeutics seller in Q4 2021 was State Street, an estimated $11.2M sold.
Based on aggregated 13F filings for Q4 2021.